关于棕色大藻在阿尔茨海默氏症疾病中的神经保护潜力的叙述性审查
Melis Cokdinleyen1, Luana Cristina Dos Santos1, Cristiano José de Andrade2
1Foodomics Lab, Institute of Food Science Research (CIAL, CSIC), 28049 Madrid, Spain.
Nutrients
|January 8, 2025
概括
棕色大藻提供天然化合物,可以对抗阿尔茨海默氏症.
科学领域:
- 神经科学和海洋生物技术
- 专注于天然产品化学和神经保护.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病.
- 目前的AD治疗有局限性和副作用.
- 棕色大藻被探索为促进健康的代谢物.
研究的目的:
- 审查最近关于棕色藻生物活性化合物的研究.
- 评估它们对抗阿尔茨海默病的神经保护性质.
- 探索它们在功能性食品和营养保健品中的潜力.
主要方法:
- 对过去五年的研究进行了全面的文献综述.
- 分析生物活性化合物,提取方法和神经保护机制.
- 对抗氧化剂,抗炎和增强认知效果的评估.
主要成果:
- 棕色大藻类含有抗氧化剂 (胡卜素,) 和omega-3脂肪酸.
- 这些化合物具有抗炎和抗氧化特性,对神经保护至关重要.
- 有证据表明,它有可能改善认知功能并降低AD风险.
结论:
- 棕色大藻类对抗阿尔茨海默病具有显著的神经保护潜力.
- 需要进一步的临床研究来验证这些发现.
- 在开发用于AD预防和管理的新型功能性食品和营养保健品方面的潜在作用.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
11.8K
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
428
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer Disease l: Introduction
38
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
38
Alzheimer Disease ll: Pathophysiology
44
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
44
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
